Abstract Mixed cryoglobulinemia is often associated with hepatic C virus infection and is less common with hepatitis B virus infection, and it often progresses into lymphoproliferative diseases. Rituximab is known to achieve systemic B-cell depletion and clinical remission of the systemic effects of cryoglobulins in hepatitis C virusassociated cryoglobulinemia. Conversely, there are few reports regarding the use of rituximab in hepatitis B virusassociated cryoglobulinemia. We report here the case of a 65-year-old Japanese female who presented with lymphoproliferative disease-related cryoglobulinemia with hepatitis B virus, including membranoproliferative glomerulonephritis with renal failure. The vasculitis was refractory to conventional and antiviral therapy, but rituximab use led to control the disease. Our case highlights the benefit and efficacy of rituximab in association with antiviral therapy in small vessel vasculitis related to lymphoproliferative disease-related cryoglobulinemia with hepatitis B virus.
Introduction
Mixed cryoglobulinemia (MC), type II and type III, refers to the presence of circulating cryoprecipitable immune complexes in the serum and manifests clinically by a classical triad of purpura, weakness, and arthralgias. MC is characterized by variable organ involvement, including skin lesions (orthostatic purpura, leukocytoclastic vasculitis), membranoproliferative glomerulonephritis (MPGN), diffuse vasculitis, and less frequently, lymphoproliferative diseases. In addition, MC is associated with numerous infectious diseases, especially hepatitis C virus (HCV) infection and less commonly with hepatitis B virus (HBV) infection. Ferri et al. investigate the demographic features of MC patients in 231 patients. They report HCV infection causes MC in 92 % of cases, whereas hepatitis B virus causes in 1.8 % of patients [1] . Treatment of HCV-MC vasculitis mainly focuses on eradication of HCV by combined interferon-ribavirin therapy. In recent study, efficacy of rituximab, a chimeric monoclonal antibody directed against CD20 antigen, is reported to treat patients who were refractory to conventional antiviral therapy or patients who have had a relapse of disease after therapy [2, 3] . However, both established treatments and efficacy of rituximab treatment for HBV-MC vasculitis are still unknown.
We report here a case of lymphoproliferative diseaserelated MC with HBV diagnosed by bone marrow biopsy during renal workup, which was refractory to antiviral therapy but in which rituximab and prednisolone led to a decline in proteinuria and normalized renal function.
A 65-year-old Japanese female patient with a 3-year history of relapsing rash, and a 3-month history of proteinuria was admitted to hospital for further investigation. She has a past medical history of hypertension treated with olmesartan, but the results of testing at least 5 years before admission reported no proteinuria or hematuria. On physical examination, her blood pressure was 158/84 mmHg, pulse was 84 beats/min, and temperature was 37.0°C. She had bilateral pitting edema of legs, extending up to her thighs. Raised purpuric lesions were noted on bilateral legs (Fig. 1) . The reminder of the physical examination, including neurologic examination was not significant. The patient did not describe symptoms that suggested the presence of Raynaud's phenomenon.
Her biochemical parameters and urinary findings are summarized in Table 1 . Protein/creatinine ratio in a spot urine specimen, 3.6 g/g Cr; urinary protein 2.7 g/day; urinary sediment revealed [100 erythrocytes and 10-19 leukocytes per high-power field, and granular casts were also noted. The hematocrit count, 26 %; hemoglobin concentration, 8.9 g/dl; platelet count, 140,000/mm 3 571 mg/dl; IgA, 165 mg/dl; IgM, 155 mg/dl; and rheumatoid factor, 167 IU/ml. Although circulating immune complexes, MPO-ANCA, proteinase 3-specific ANCA and anti-GBM antibody were negative, serum complement levels were decreased (C3, 45 mg/dl; C4, 5.9 mg/dl; CH50, \5 IU/ml). Qualitative serum cryoglobulin level was positive. Viral screening was negative for hepatitis C by serology and polymerase chain reaction. A test for hepatitis B surface antibody was positive while a test for hepatitis B surface antigen was negative. The hepatitis B viral load was undetectable. A test for hepatitis B e-antigen was negative, and a test for hepatitis B e-antibody was positive, suggesting the possibility of mutation. Abdominal ultrasound and computed tomography showed normal-sized liver with no significant findings and normal-sized kidneys. Renal biopsy findings (Fig. 2) show mild proliferation of mesangial cells and increase of mesangial matrix, diffuse segmental endocapillary hypercellularity with double contour, and intracapillary hyaline-like deposits were observed in the light microscopic study (Fig. 2a ) along with the findings of glomerular capillary endotheliosis characterized by narrowed or obstructed capillary lumina with endothelial cell swelling and hypertrophy. Immunofluorescence staining (Fig. 2b ) demonstrated deposits of IgM and C3 in the glomerular basement region. Electron microscopic study showed highly organized fibrillar structures consistent with cryoglobulins ( Fig. 2c ) and electron-dense deposits (Fig. 2d) were observed in the subendothelial and mesangial regions. A skin biopsy specimen of a purpuric lesion revealed leukocytoclastic vasculitis (Fig. 3) . Serum protein electrophoresis showed gammopathy with two distinct monoclonal peaks consisting of IgG kappa and IgG lambda, respectively. The kappa/ lambda ratio was 5.0 (normal range 0.26-1.65), free kappa light chains 109.0 mg/l, free lambda light chains 21.8 mg/l, and there was evidence of Bence Jones proteins on the urine protein electrophoresis. Further workup for lymphoproliferative diseases including amyloidosis, rectal biopsy, bone marrow biopsy and inguinal lymph node biopsy were performed. Rectal biopsy specimens were not stained with Congo red. Bone marrow biopsy revealed hypocellularity, with several lymphoplasmacytic aggregates (Fig. 4a, b ).
Immunohistochemical stains (Fig. 4c-e) showed that the lymphocytes were positive for kappa ( Fig. 4c) and lambda ( Fig. 4d ) light chains as well as CD20 (Fig. 4e) . A biopsy of an enlarged 2-cm right inguinal lymph node showed it was effaced by a diffuse, polymorphous proliferation of small-sized lymphoid cells (Fig. 5a) . Immunohistochemical stains demonstrated that most of the lymphoid infiltrate was composed of CD20-positive B cells (Fig. 5b) , with fewer CD3-positive T cells (Fig. 5c) . In situ hybridization for immunoglobulin kappa light chains (Fig. 5d ) and lambda light chains (Fig. 5e) showed only scattered lymphoid cells. A diagnosis of cryoglobulinemic vasculitis associated with MPGN was made. This case also had expansion of the peripheral B-lymphocyte pool and lymphoid infiltrates with the lymph node and bone marrow consistent with overt B-cell lymphoproliferative disease. Antiviral therapy with entecavir was initiated because the hepatitis B viral load became slightly positive at 100,000 copies/mL before immunosuppressive treatment. Thereafter, treatment started with intravenous methylprednisolone (0.5 g/day for 3 days) and oral prednisolone (40 mg daily), which was gradually tapered off in the next 4 weeks. Two weeks later, our patient received a monoclonal anti-CD20 antibody, rituximab, 375 mg/m 2 , as 4-weekly infusions with oral prednisolone (20 mg/day) because of gradual deterioration in renal function and an increase in the kappa/lambda ratio up to 14.7. This led to a depletion of circulating B cells. The proteinuria declined and her renal function returned to normal. The time to clinical response was 35 days after the initiation of therapy (definition of clinical response in this case is defined as improvement of[50 % or normalization in all renal parameters that were normal at baseline [4] ). Her kappa/lambda ratio came down to normal range of 1.6. The HBV viral load became undetectable. The patient was fine, and took medication entecavir and olmesartan. The serum creatinine level and the kappa/lambda ratio remain within normal range at 7 months after the initiation of therapy (Fig. 6 ). Urinary findings also improved after the treatment ( Table 2 ). The HBV viral load remained undetectable. Fig. 4 Bone marrow biopsy. a Bone marrow biopsy specimen has an overall cellularity of 30 %, which is hypocellular, with maturing trilineage hematopoiesis (9100). b A few small aggregates composed of plasma cells and lymphocytes have displaced normal hematopoietic elements (9400). c Immunohistochemical staining of the specimen from the bone marrow core biopsy shows positive for kappa light chain (9400). d Immunohistochemical staining of the specimen from the bone marrow core biopsy shows positive for lambda light chain (9400). e Immunohistochemical staining of the specimen from the bone marrow core biopsy shows positive for CD20 (9100)
Discussion
In this case, we made two important clinical observations. First of all, rituximab significantly improves MC vasculitis and several clinical and immunologic parameters in a patient with lymphoproliferative disease-related MC with HBV who had been resistant to standard immunosuppression therapies. Second, serum free light chain (FLC) ratio would be a useful maker for response to rituximab therapy.
First, rituximab significantly improves MC vasculitis and several clinical and immunologic parameters in a patient with lymphoproliferative disease-related MC with HBV who had been resistant to standard immunosuppression therapies. Recently, rituximab has been used to treat a variety of hematological plasma cell disorders. It may interfere with monoclonal IgM production, cryoglobulin synthesis and renal deposition of immune complexes [2] . They have reported the efficacy and safety of rituximab in type II mixed cryoglobulinemia [3, 5] , and the nephritis went into remission in one of their patients [6] . De Vita et al. [7] conduct a long-term, prospective, randomized controlled trial evaluating rituximab monotherapy compared with conventional treatment group (glucocorticoids, azathioprine, or cyclophosphamide). They reported that the median duration of clinical response was 18 months in rituximab group [7] . In HCV-MC, it has been shown to reduce the cryoglobulin levels, significantly improve the cutaneous vasculitis in patients who had been resistant to interferon-alpha [6] , and normalize the bone marrow B-cell infiltration [2] . However, there is no clinical evidence whether rituximab is effective in lymphoproliferative disease-related MC with HBV, and in particular, there has been only one case report in the literature on the use of rituximab in HBV-MC [8] . Several researchers have reported the occurrence of severe side effects following rituximab therapy in MC. Sene et al. [9] reported systemic (9400) drug reactions including flare of vasculitis and serum sickness after rituximab, but those patients received highdose rituximab protocol cycle with 1,000 mg on days 1 and 15. On the other hand, Terrier et al. [10] described severe infections occurring in a particular subsets of patients aged [70 years, renal failure with a glomerular filtration rate of \60 ml/min, and long-term use of high-dose corticosteroids. This case fits most of these risk factors, but we need to be aware that they excluded HBV-infected individuals. Additionally, Hanbali et al. [11] described hepatitis B reactivation is increasingly recognized complications following Rituximab therapy. They emphasize the importance of hepatitis B DNA viral load monitoring during rituximab therapy. We treated successfully without major side effects because the patient was aged \70 years, was using the 375 mg rituximab protocol, and it was possible to taper off corticosteroids early in the course of treatment.
Second, serum FLC ratio would be a useful maker for response to rituximab therapy. B-cell depletion therapy with rituximab dramatically improved abnormalities in B-cell homeostasis, with a normalization of serum FLC ratio after treatment. Some investigators [12] [13] [14] reported abnormal serum FLC ratio is a significant predictor of progression to myeloma. Bradwell et al. [15] indicated that the FLC ratio may be a more accurate measure of changes in production of FLC than individual light-chain concentrations in multiple myeloma patients because the short half-life of free light-chains in serum (2-4 h) allows earlier assessment of changes in tumor mass than can be achieved by monitoring of changes in intact immunoglobulin (IgG half-life is 20-25 days). As previously described, the individual quantitation of free kappa and lambda chains would be affected by the kidney function [12] , but the FLC ratio compensates for alterations in glomerular filtration rate [14] . These results may support that the FLC ratio can be used to monitor response to therapy in patients with lymphoproliferative disease-related MC with HBV. To the best of our knowledge, the present case should be the first to demonstrate the usefulness of serum FLC ratio to monitor response to rituximab therapy in MC.
This case report has limitation that must be weighted. The disease control may not be solely by the effect of rituximab, but combined effect of rituximab and glucocorticoids. High doses or pulsed doses of glucocorticoids are reported to help manage severe cryoglobulinemia, such as renal and neurologic involvement [16] .
In conclusion, we report a case of lymphoproliferative disease-related MC with HBV, successfully treated with the simultaneous blockade of both the HBV infection and the B-cell proliferations by means of combined therapy of antiviral, prednisolone and rituximab. This case indicates that rituximab may represent a safe and effective therapeutic option for lymphoproliferative disease-related MC and serum FLC ratio could be used to monitor response to Hospital Days Fig. 6 The FLC ratio and serum creatinine level during the disease course rituximab therapy. Future controlled, randomized studies are needed to define the drug indications and the costefficacy profile in the different systemic features of the disease. In addition, the duration of response to rituximab also should be assessed using serum FLC ratio.
